Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)

Next Previous
Trial Profile

A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceritinib (Primary)
  • Indications Anaplastic large cell lymphoma; Cancer; Glioma; Muscle tissue neoplasms; Neuroblastoma; Rhabdomyosarcoma; Sarcoma; Thyroid cancer
  • Focus Adverse reactions
  • Acronyms ASCEND-1
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 01 Jan 2022 Results of exploratory analysis of genetic determinants of response to ceritinib using tumor biopsies from anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small-cell lung cancer (NSCLC) patients, published in the Lung Cancer.
    • 12 Nov 2021 Results published in the Lancet Oncology
    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top